Integrin agonists or activating compounds and methods for making and using same
US12109263B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Sep 10, 2021 |
| Grant date | Oct 8, 2024 |
| Priority date | — |
| Expiry date | Sep 10, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55511
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Small molecule integrin agonists or integrin activating compounds including at least one di-alkylaryl amine end group and at least one alkyl or alkenoxy linking group including at least one protonatable moiety, wherein the compounds enhance vaccine efficacies, enhance adoptive cell therapy efficacies, enhance immunotherapy efficacies, enhance therapeutic antibody therapy efficacies, enhance checkpoint inhibitor therapy efficacies, enhance effector cell therapy efficacies, and enhanced cell based transplant efficacies and wherein at protonatable moiety either protonate at biological pHs or bears a charge with associated pharmaceutically acceptable counterion making the compound water soluble to improve bioavailability and methods for making and using same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.